Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board
February 09, 2022 03:01 ET | Mainz BioMed NV
Former DANAHER, ROCHE & QIAGEN Business Development Executive with Over 25 Years of Experience within the Pharmaceuticals and Diagnostics Industry BERKELEY, Calif. and MAINZ, Germany, Feb. ...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert
February 04, 2022 03:01 ET | Mainz BioMed NV
Results to impact ColoAlert profile for FDA submission Provides opportunity for ColoAlert to achieve gold standard status as the premier at-home screening test for colorectal cancer BERKELEY, Calif....
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 28, 2022 16:05 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Appoints Steve Quinn as VP Business Development
January 27, 2022 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Announces Pricing of Follow-on Offering
January 25, 2022 20:00 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert
January 19, 2022 03:01 ET | Mainz BioMed NV
Results of European study potentially incorporated into U.S. regulatory strategy for FDA approval Opportunity for ColoAlert to become the gold standard at-home screening test for colorectal cancer ...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche Diagnostics Business Development, to Strategic Advisory Board
January 12, 2022 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 11, 2022 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers
January 05, 2022 03:01 ET | Mainz BioMed NV
Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz BioMed Appoints Karen Richards as Vice President, Regulatory Affairs to Lead US FDA Approval Process
December 21, 2021 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...